DZ2685A1 - Formulation pharmaceutique orale à libération prolongée. - Google Patents

Formulation pharmaceutique orale à libération prolongée.

Info

Publication number
DZ2685A1
DZ2685A1 DZ980295A DZ980295A DZ2685A1 DZ 2685 A1 DZ2685 A1 DZ 2685A1 DZ 980295 A DZ980295 A DZ 980295A DZ 980295 A DZ980295 A DZ 980295A DZ 2685 A1 DZ2685 A1 DZ 2685A1
Authority
DZ
Algeria
Prior art keywords
sustained release
pharmaceutical formulation
release pharmaceutical
oral sustained
oral
Prior art date
Application number
DZ980295A
Other languages
English (en)
French (fr)
Inventor
Per Gummar Karehill
Per Johan Lundberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Application granted granted Critical
Publication of DZ2685A1 publication Critical patent/DZ2685A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DZ980295A 1997-12-22 1998-12-16 Formulation pharmaceutique orale à libération prolongée. DZ2685A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704869A SE9704869D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulaton II

Publications (1)

Publication Number Publication Date
DZ2685A1 true DZ2685A1 (fr) 2003-03-29

Family

ID=20409571

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980295A DZ2685A1 (fr) 1997-12-22 1998-12-16 Formulation pharmaceutique orale à libération prolongée.

Country Status (38)

Country Link
US (1) US6605303B1 (enExample)
EP (1) EP1043976B1 (enExample)
JP (1) JP4865945B2 (enExample)
KR (2) KR20060097069A (enExample)
CN (1) CN1171582C (enExample)
AR (1) AR017201A1 (enExample)
AT (1) ATE312602T1 (enExample)
AU (1) AU759634B2 (enExample)
BG (1) BG65028B1 (enExample)
BR (1) BR9814378A (enExample)
CA (1) CA2315261C (enExample)
CY (1) CY1106072T1 (enExample)
CZ (1) CZ299228B6 (enExample)
DE (1) DE69832816T2 (enExample)
DK (1) DK1043976T3 (enExample)
DZ (1) DZ2685A1 (enExample)
EE (1) EE04901B1 (enExample)
ES (1) ES2252875T3 (enExample)
HR (1) HRP20000380B1 (enExample)
HU (1) HUP0101437A3 (enExample)
IL (2) IL136827A0 (enExample)
IS (1) IS5524A (enExample)
MA (1) MA26576A1 (enExample)
MY (1) MY126555A (enExample)
NO (1) NO20003218L (enExample)
NZ (1) NZ505127A (enExample)
PL (1) PL193776B1 (enExample)
RU (1) RU2214232C2 (enExample)
SA (1) SA99191077B1 (enExample)
SE (1) SE9704869D0 (enExample)
SK (1) SK284988B6 (enExample)
TN (1) TNSN98229A1 (enExample)
TR (1) TR200001981T2 (enExample)
TW (1) TWI249410B (enExample)
UA (1) UA69397C2 (enExample)
WO (1) WO1999032091A1 (enExample)
YU (1) YU36700A (enExample)
ZA (1) ZA9811239B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE286394T1 (de) * 1995-09-21 2005-01-15 Pharma Pass Ii Llc Ein säurelabile omeprazol enthaltende arzneizusammensetzung und verfahren zu deren herstellung
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
ATE500815T1 (de) 1997-12-08 2011-03-15 Dietrich Rango Neue suppositoriumsform mit säureempfindlichem wirkstoff
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
WO2002045694A1 (en) * 2000-12-07 2002-06-13 Altana Pharma Ag Rapidly disintegrating tablet comprising an acid-labile active ingredient
JP4848101B2 (ja) * 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
MXPA05003162A (es) 2002-09-26 2005-07-05 Yamanouchi Pharma Co Ltd Agentes mejoradores de absorbibilidad de droga.
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4493970B2 (ja) * 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
CA2519208A1 (en) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
WO2005012289A1 (en) * 2003-07-17 2005-02-10 Altana Pharma Ag Novel salt of (r) - pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US20090124702A1 (en) * 2005-01-25 2009-05-14 Pechetti Siva Satya Krishna Babu Pharmaceutical Compositions of Metformin
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
DE102005060393A1 (de) * 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
CN101389316A (zh) * 2005-12-28 2009-03-18 武田药品工业株式会社 控制释放固体制剂
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
WO2008094877A2 (en) * 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US8679541B2 (en) * 2007-03-14 2014-03-25 Particle Dynamics International, Llc Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
RU2010119041A (ru) * 2007-10-12 2011-11-20 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
US8945622B2 (en) 2009-03-09 2015-02-03 Council Of Scientific And Industrial Research Sustained release composition of therapeutic agent
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
HRP20191559T1 (hr) 2013-02-13 2019-11-29 Redhill Biopharma Ltd Farmaceutski pripravci za liječenje infekcije bakterijom helicobacter pylori
CN104721185A (zh) * 2013-12-21 2015-06-24 辰欣药业股份有限公司 一种提高埃索美拉唑钠稳定性的方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US5229181A (en) * 1990-10-30 1993-07-20 Amber Technologies Tubular knit cleanroom wiper
TW209174B (enExample) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
US5178867A (en) * 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
KR100355130B1 (ko) * 1992-09-18 2003-01-30 야마노우치세이야쿠 가부시키가이샤 하이드로겔서방성정제
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
JPH07330629A (ja) * 1994-06-02 1995-12-19 Nippon Shokubai Co Ltd 徐放性製剤
DK1078628T3 (da) * 1994-07-08 2009-02-23 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
BR9508261A (pt) * 1994-07-08 1997-12-23 Astra Ab Formulação oral entericamente revestida uso da mesma processo para preparer a formulação inibir a secreção de ácido gástrico em mamíferos e no ser humano e tratar doenças relacionadas ao ácido gástrico em maníferos e no ser humano e pacote de empola de pressão transversal
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
AU3290397A (en) * 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US7016717B2 (en) * 2002-07-05 2006-03-21 The Regents Of The University Of California Near-infrared spectroscopic tissue imaging for medical applications
ITPD20050230A1 (it) * 2005-07-28 2007-01-29 Marcato Spa Macchina ad uso domestico per la estrusione di paste alimentari fresche

Also Published As

Publication number Publication date
KR20010033428A (ko) 2001-04-25
CZ20002314A3 (cs) 2000-11-15
HK1034455A1 (en) 2001-10-26
ATE312602T1 (de) 2005-12-15
AU759634B2 (en) 2003-04-17
IL136827A (en) 2007-05-15
TWI249410B (en) 2006-02-21
SK284988B6 (sk) 2006-04-06
BR9814378A (pt) 2000-10-10
TR200001981T2 (tr) 2000-11-21
YU36700A (sh) 2003-01-31
US6605303B1 (en) 2003-08-12
EP1043976A1 (en) 2000-10-18
PL193776B1 (pl) 2007-03-30
IS5524A (is) 2000-06-08
CZ299228B6 (cs) 2008-05-21
BG104620A (en) 2001-04-30
CN1284866A (zh) 2001-02-21
AR017201A1 (es) 2001-08-22
AU1991299A (en) 1999-07-12
WO1999032091A1 (en) 1999-07-01
RU2214232C2 (ru) 2003-10-20
MY126555A (en) 2006-10-31
SE9704869D0 (sv) 1997-12-22
EE04901B1 (et) 2007-10-15
EE200000383A (et) 2001-12-17
NZ505127A (en) 2003-02-28
HRP20000380A2 (en) 2001-06-30
TNSN98229A1 (fr) 2005-03-15
SA99191077B1 (ar) 2006-07-11
DE69832816D1 (de) 2006-01-19
MA26576A1 (fr) 2004-12-20
DK1043976T3 (da) 2006-03-20
HRP20000380B1 (en) 2007-08-31
JP2001526211A (ja) 2001-12-18
ZA9811239B (en) 1999-06-22
NO20003218D0 (no) 2000-06-21
KR100755154B1 (ko) 2007-09-04
HUP0101437A2 (hu) 2001-10-28
EP1043976B1 (en) 2005-12-14
CN1171582C (zh) 2004-10-20
CA2315261A1 (en) 1999-07-01
PL341428A1 (en) 2001-04-09
SK8072000A3 (en) 2001-01-18
IL136827A0 (en) 2001-06-14
UA69397C2 (uk) 2004-09-15
ES2252875T3 (es) 2006-05-16
JP4865945B2 (ja) 2012-02-01
CA2315261C (en) 2008-02-12
BG65028B1 (bg) 2006-12-29
NO20003218L (no) 2000-08-22
CY1106072T1 (el) 2011-06-08
HUP0101437A3 (en) 2003-01-28
DE69832816T2 (de) 2006-08-31
KR20060097069A (ko) 2006-09-13

Similar Documents

Publication Publication Date Title
DZ2686A1 (fr) Formulation pharmaceutique orale à libération pulsée.
ID24654A (id) Formulasi farmasi omeprazola
MA26576A1 (fr) Formulation pharmaceutique orale a liberation prolongee
TR199901077A3 (tr) Ispençiyari formülasyonlar.
MA26549A1 (fr) Medicaments
DE69525148D1 (de) Pharmazeutische formulierung
BR9610153A (pt) Formulações farmacêuticas
NO20012915D0 (no) Ny farmasöytisk formulering
BR9611626A (pt) Formulações farmacéuticas
TR199800631A3 (tr) Ecza formülasyonu.
DE69621885D1 (de) Neue galenische orale pharmazeutische formulierung
NO980546D0 (no) Farmasöytiske midler
BR9607752B1 (pt) formulação farmacêutica de microcápsula de liberação controlada.
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
NO993096D0 (no) Orale cyklosporinformuleringer
BR9610396A (pt) Formulação farmacêutica
PT868911E (pt) Formulacoes de rapamicina para administracao oral
ID30032A (id) Formulasi farmasi
DZ1926A1 (fr) Formulations pharmaceutiques.
ID16781A (id) Formulasi-formulasi farmasi
ATE295150T1 (de) Pharmazeutische zusammensetzungen
ITMI941169A0 (it) Formulazioni farmaceutiche
AR025867A1 (es) Formulacion portasdora farmaceutica
EE200000330A (et) Farmatseutilised kompositsioonid
FI973230L (fi) Uusi farmaseuttinen formulaatio